Close Menu

NEW YORK – Angiocare will distribute Spartan Bioscience's test for CYP2C19 mutations, the firms announced on Thursday.

The deal covers the Netherlands, where Angiocare is based, although it may eventually cover other geographies, a spokesperson for Spartan Bio said. She declined to disclose further details.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.